The return of EO9: A bioreductive indoloquinone targeted at bladder cancer

被引：0
|
作者：
Phillips, RM [1 ]
机构：
[1] Inst Canc Therapeut, Bradford, W Yorkshire, England
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：32 / 32
页数：1
相关论文
共 50 条
  • [21] The autoxidation of the reduced forms of EO9
    Butler, J
    Spanswick, VJ
    Cummings, J
    FREE RADICAL RESEARCH, 1996, 25 (02) : 141 - 148
  • [22] Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species
    Bailey, SM
    Lewis, AD
    Patterson, LH
    Fisher, GR
    Knox, RJ
    Workman, P
    BIOCHEMICAL PHARMACOLOGY, 2001, 62 (04) : 461 - 468
  • [23] INDOLOQUINONE EO9 - DNA INTERSTRAND CROSS-LINKING UPON REDUCTION BY DT-DIAPHORASE OR XANTHINE-OXIDASE
    MALIEPAARD, M
    WOLFS, A
    GROOT, SE
    DEMOL, NJ
    JANSSEN, LHM
    BRITISH JOURNAL OF CANCER, 1995, 71 (04) : 836 - 839
  • [24] Stability experiments in human urine with EO9 (apaziquone): A novel anticancer agent for the intravesical treatment of bladder cancer
    Vainchtein, Liia D.
    Rosing, Hilde
    Mirejovsky, Dorla
    Lenaz, Luigi
    Schellens, Jan H. M.
    Beijnen, Jos H.
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2007, 43 (01) : 285 - 292
  • [25] Phase I clinical evaluation of intravesical EOquin (EO9) against superficial bladder cancer: Preliminary results.
    Puri, R
    Basu, S
    Loadman, P
    Martin, SW
    Palit, V
    Lenaz, G
    Van Kalken, C
    Naylor, B
    Phillips, RM
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6248S - 6249S
  • [26] Manufacturing of a lyophilized parenteral dosage form of the indoloquinone antitumor agent EO9 for phase II clinical studies in the setting of a hospital pharmacy
    JonkmanDeVries, JD
    Henrar, REC
    Bult, A
    Beijnen, JH
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1997, 23 (02) : 137 - 144
  • [27] SENSITIVE ISOCRATIC HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF A NOVEL INDOLOQUINONE CYTOTOXIC DRUG (EO9) IN HUMAN PLASMA AND URINE
    SCHELLENS, JHM
    LOOS, W
    BEIJNEN, JH
    STOTER, G
    VERWEIJ, J
    JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1993, 615 (02): : 309 - 315
  • [28] AN IMPROVED SYNTHESIS OF THE INDOLEQUINONE ANTICANCER AGENT EO9
    COTTERILL, AS
    MOODY, CJ
    ROFFEY, JRA
    TETRAHEDRON, 1995, 51 (26) : 7223 - 7230
  • [29] POTENTIATION OF EO9 ANTITUMOR-ACTIVITY BY HYDRALAZINE
    BIBBY, MC
    SLEIGH, NR
    LOADMAN, PM
    DOUBLE, JA
    EUROPEAN JOURNAL OF CANCER, 1993, 29A (07) : 1033 - 1035
  • [30] THE ROLE OF NAD(P)H - QUINONE REDUCTASE (EC 1.6.99.2, DT-DIAPHORASE) IN THE REDUCTIVE BIOACTIVATION OF THE NOVEL INDOLOQUINONE ANTITUMOR AGENT EO9
    WALTON, MI
    SMITH, PJ
    WORKMAN, P
    CANCER COMMUNICATIONS, 1991, 3 (07): : 199 - 206
12345